Please login to the form below
Merck & Co's Dr Daniel Pascheles joins Molekule Consulting
He becomes the biopharma services provider’s CEO
Miami, US-based Molekule Consulting has appointed Dr Daniel Pascheles as its new chief executive officer.
Dr Daniel Pascheles joins from Merck & Co, where he served as vice president and head of global competitive intelligence for the last 12 years.
While at Merck, Dr Pascheles provided strategy development, target and candidate identification for the firm's licensing, business development and M&A activities, alongside leading the CI department.
Prior to this, Dr Pascheles worked at Aventis Pharmaceuticals - as well as its predecessor companies - for over 14 years, latterly as its vice president.
His previous roles include head of global competitive intelligence, global marketing director, general manager of Switzerland and European head of sales, marketing administration and strategic planning.
David Alderman, Molekule Consulting's founder and president, said: “Dr Pascheles is one of the most experienced, ethical and well-respected CI professionals in our industry; he is a global leader who brings expertise and exceptional vision to build our growing company.”
Subscribe to our email news alerts
- Pfizer’s RSV vaccine granted MHRA approval to protect infants and older adults
- Novavax’s updated COVID-19 vaccine granted Emergency Use Listing by WHO
- FDA to investigate risk of T-cell malignancy from CAR-T cell immunotherapies
- Boehringer Ingelheim and IBM announce AI antibody drug discovery partnership
- New blood test to reduce heart attacks and death rates in A&E heart patients
- Clairvoyant commercialisation
No results were found
PMHub
IGNIFI
We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...
Latest intelligence
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
- The problem with clinical trials (and how virtual insight-gathering can help)
- While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
- The rise of digital healthcare – fuelled by open innovation in healthtech hubs
- How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of drug development...
